Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8101 to 8115 of 8134 results

  1. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  2. Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]

    In development [GID-TA11106] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]

    In development [GID-TA11132] Expected publication date: 26 June 2024

    Technology appraisal guidance
    In development

  4. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID6129]

    In development [GID-TA11033] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Lisocabtagene maraleucel for treating relapsed or refractory diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal large B-cell lymphoma or follicular lymphoma grade 3B after first-line chemotherapy [ID3887]

    In development [GID-TA10778] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  6. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  8. Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]

    Awaiting development [GID-TA11366] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

    Interventional procedures guidance
    Discontinued

  10. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  11. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  12. Surgical correction of hallux valgus using minimal access techniques

    In development [GID-IPG10339] Expected publication date: 20 June 2024

    Interventional procedures guidance
    In development

  13. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  15. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

    Interventional procedures guidance
    Discontinued